SILEXION THERAPEUTICS CORP (SLXN) Fundamental Analysis & Valuation

NASDAQ:SLXN • KYG1281K1307

Current stock price

1.05 USD
+0.06 (+6.06%)
Last:

This SLXN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SLXN Profitability Analysis

1.1 Basic Checks

  • In the past year SLXN has reported negative net income.
  • In the past year SLXN has reported a negative cash flow from operations.
  • In the past 5 years SLXN reported 4 times negative net income.
  • In the past 5 years SLXN reported 4 times negative operating cash flow.
SLXN Yearly Net Income VS EBIT VS OCF VS FCFSLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of SLXN (-165.10%) is worse than 85.47% of its industry peers.
  • SLXN's Return On Equity of -457.63% is on the low side compared to the rest of the industry. SLXN is outperformed by 76.74% of its industry peers.
Industry RankSector Rank
ROA -165.1%
ROE -457.63%
ROIC N/A
ROA(3y)-279.76%
ROA(5y)-167.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLXN Yearly ROA, ROE, ROICSLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 1K -1K -2K

1.3 Margins

  • SLXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLXN Yearly Profit, Operating, Gross MarginsSLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. SLXN Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for SLXN has been increased compared to 1 year ago.
  • The number of shares outstanding for SLXN has been reduced compared to 5 years ago.
  • SLXN has a better debt/assets ratio than last year.
SLXN Yearly Shares OutstandingSLXN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 5M 10M
SLXN Yearly Total Debt VS Total AssetsSLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -14.95, we must say that SLXN is in the distress zone and has some risk of bankruptcy.
  • SLXN has a worse Altman-Z score (-14.95) than 80.62% of its industry peers.
  • A Debt/Equity ratio of 0.60 indicates that SLXN is somewhat dependend on debt financing.
  • SLXN has a worse Debt to Equity ratio (0.60) than 72.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -14.95
ROIC/WACCN/A
WACCN/A
SLXN Yearly LT Debt VS Equity VS FCFSLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.41 indicates that SLXN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.41, SLXN is doing worse than 71.90% of the companies in the same industry.
  • A Quick Ratio of 2.41 indicates that SLXN has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.41, SLXN is doing worse than 68.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.41
SLXN Yearly Current Assets VS Current LiabilitesSLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SLXN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 92.30% over the past year.
EPS 1Y (TTM)92.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SLXN will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.45% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.38%
EPS Next 2Y34.83%
EPS Next 3Y21.24%
EPS Next 5Y11.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLXN Yearly EPS VS EstimatesSLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. SLXN Valuation Analysis

4.1 Price/Earnings Ratio

  • SLXN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLXN Price Earnings VS Forward Price EarningsSLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLXN Per share dataSLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • SLXN's earnings are expected to grow with 21.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.83%
EPS Next 3Y21.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLXN Dividend Analysis

5.1 Amount

  • No dividends for SLXN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLXN Fundamentals: All Metrics, Ratios and Statistics

SILEXION THERAPEUTICS CORP

NASDAQ:SLXN (4/14/2026, 2:00:52 PM)

1.05

+0.06 (+6.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17
Earnings (Next)N/A
Inst Owners5.17%
Inst Owner ChangeN/A
Ins Owners5.17%
Ins Owner Change29.77%
Market Cap3.50M
Revenue(TTM)N/A
Net Income(TTM)-11.91M
Analysts82.5
Price Target6.12 (482.86%)
Short Float %1.67%
Short Ratio0.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.8%
Min EPS beat(2)-22.55%
Max EPS beat(2)16.95%
EPS beat(4)1
Avg EPS beat(4)-9.78%
Min EPS beat(4)-22.55%
Max EPS beat(4)16.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.26%
EPS NY rev (3m)6.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-12.5
EYN/A
EPS(NY)-4.2
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-3.25
OCFYN/A
SpS0
BVpS0.78
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -165.1%
ROE -457.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-279.76%
ROA(5y)-167.89%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.41
Altman-Z -14.95
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)59.65%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.55%
EPS Next Y66.38%
EPS Next 2Y34.83%
EPS Next 3Y21.24%
EPS Next 5Y11.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.86%
OCF growth 3YN/A
OCF growth 5YN/A

SILEXION THERAPEUTICS CORP / SLXN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SILEXION THERAPEUTICS CORP (SLXN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SLXN.


Can you provide the valuation status for SILEXION THERAPEUTICS CORP?

ChartMill assigns a valuation rating of 1 / 10 to SILEXION THERAPEUTICS CORP (SLXN). This can be considered as Overvalued.


How profitable is SILEXION THERAPEUTICS CORP (SLXN) stock?

SILEXION THERAPEUTICS CORP (SLXN) has a profitability rating of 0 / 10.


What is the financial health of SILEXION THERAPEUTICS CORP (SLXN) stock?

The financial health rating of SILEXION THERAPEUTICS CORP (SLXN) is 3 / 10.